Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 32Thoracic 2Sarcoma 2Gynecologic 2Gastrointestinal 2Dermatologic 2NET 1Lymphoid 1Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 148Gastro-enteropancreatic neuroendocrine tumor 29Carcinoma, Neuroendocrine 18Neoplasms 16Breast Neoplasms 13Adenoma, Islet Cell 13Prostatic Neoplasms 11Carcinoma, Hepatocellular 11Carcinoid Tumor 11Stomach Neoplasms 10Pheochromocytoma 10Pancreatic Neoplasms 10Colorectal Neoplasms 10Sarcoma 9Paraganglioma 9Thyroid Neoplasms 8Neoplasm Metastasis 8Lung Neoplasms 8Cholangiocarcinoma 8Small Cell Lung Carcinoma 7Ovarian Neoplasms 7Melanoma 7Esophageal Neoplasms 7Anus Neoplasms 7Rectal Neoplasms 6Mesothelioma 6Colonic Neoplasms 6Carcinoma 6Brain Neoplasms 6Uterine Cervical Neoplasms 5

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × NET × 1 year × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡